| Project/Area Number |
09672302
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical sociology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
INOUE Yuji Yamaguchi University, Hospital, Professor, 医学部附属病院, 教授 (80213180)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 1998: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1997: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | Chronic Hepatitis C / Interferon / Cost-effectiveness Analysis / Decision Analysis / Medical Decision Sciences |
|---|
| Research Abstract |
Chronic Hepatitis C infection is the most common cause of chronic liver disease in Japan, and it results in deaths caused by liver cirrhosis and hepatocellular carcinoma. A single course of interferon alpha for patients with histologically mild chronic hepatitis C shouId prolong life expectancy at a reasonable marginal cost per year of life gained. We employed decision analysis utilizing a Markov model to project the life time clinical and economic outcomes. Though 47 % of life time costs of a 35 year old with mild chronic hepatitis C was spent for Interferon therapy in Japan and 30 % of them in the U.S., it was cost-effective. On thee other hand, 21% of the costs for hepatocellular carcinoma in Japan and 25% of the costs for liver transplantation in the U.S.contributed a little to life year prolongation. Lifetime costs for the treatment of chronic hepatitis C in Japan were higher than those in the U.S.. Frequent outpatient visits was a major causes to push up the total life time costs.
|
